Tommaso Vincenzo Bartolotta1,2, Alessia Angela Maria Orlando3, Mariangela Dimarco2, Calogero Zarcaro1, Fabiola Ferraro1, Alessandra Cirino1, Domenica Matranga4, Salvatore Vieni5, Daniela Cabibi6. 1. Department of Biomedicine, Neuroscience and Advanced Diagnostic (Bi.N.D.), University Hospital "Policlinico P. Giaccone", Via Del Vespro 129, 90127, Palermo, Italy. 2. Fondazione Istituto G.Giglio, Cefalù, PA, Italy. 3. Department of Biomedicine, Neuroscience and Advanced Diagnostic (Bi.N.D.), University Hospital "Policlinico P. Giaccone", Via Del Vespro 129, 90127, Palermo, Italy. orlandoalessiamed@hotmail.it. 4. Department of Health Promotion and Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University Hospital "Policlinico P. Giaccone", Palermo, Italy. 5. Division of General and Oncological Surgery, Department of Surgical, Oncological and Oral Sciences, University Hospital "Policlinico P. Giaccone", Palermo, Italy. 6. Anatomic Pathology Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University Hospital "Policlinico P. Giaccone", Palermo, Italy.
Abstract
PURPOSE: To assess the role of 2D-shear wave elastography (2D-SWE) in differentiating benign from malignant focal breast lesions (FBLs), providing new vendor-specific cutoff values. METHODS: 158 FBLs (size: 3.5-50 mm) detected in 151 women (age: 21-87 years) were prospectively evaluated by means 2D-SWE. For each lesion, an expert radiologist assessed US BI-RADS category and calculated the following four 2D-SWE parameters: (1) elasticity maximum (Emax); (2) mean elasticity (Emean); (3) minimum elasticity (Emin); (4) elasticity ratio (Eratio). US-guided core-biopsy was considered as standard of reference for all the FBLs classified as BI-RADS 4 or 5. For each 2D-SWE parameter, the optimal cutoff value for a diagnostic test was calculated using the Youden method. Diagnostic performance of the US BI-RADS and 2D-SWE parameters was calculated accordingly. RESULTS: 83/158 (52.5%) FBLs were benign and 75/158 (47.5%) were malignant. Statistically significant higher stiffness values were observed in malignant FBLs for all 2D-SWE parameters than in benign ones (p < 0.001). 2D-SWE cutoff values were 82.6 kPa, 66.0 kPa and 53.6 kPa, respectively, for Emax, Emean, Emin and 330.8% for Eratio. The 2D-SWE parameter showing the best diagnostic accuracy was Emax (85.44%). Considering US BI-RADS 3 (n = 60) and 4a (n = 32) FBLs, Emax and Emean showed the best diagnostic accuracy (85.87% for both), without a statistically significant decrease in sensitivity (p = 0.7003 and p = 1, respectively). CONCLUSION: Our study provides new vendor-specific cutoff values for 2D-SWE, suggesting its possible clinical use in the adjunctive assessment of category US-BI-RADS 3 and 4a breast masses.
PURPOSE: To assess the role of 2D-shear wave elastography (2D-SWE) in differentiating benign from malignant focal breast lesions (FBLs), providing new vendor-specific cutoff values. METHODS: 158 FBLs (size: 3.5-50 mm) detected in 151 women (age: 21-87 years) were prospectively evaluated by means 2D-SWE. For each lesion, an expert radiologist assessed US BI-RADS category and calculated the following four 2D-SWE parameters: (1) elasticity maximum (Emax); (2) mean elasticity (Emean); (3) minimum elasticity (Emin); (4) elasticity ratio (Eratio). US-guided core-biopsy was considered as standard of reference for all the FBLs classified as BI-RADS 4 or 5. For each 2D-SWE parameter, the optimal cutoff value for a diagnostic test was calculated using the Youden method. Diagnostic performance of the US BI-RADS and 2D-SWE parameters was calculated accordingly. RESULTS: 83/158 (52.5%) FBLs were benign and 75/158 (47.5%) were malignant. Statistically significant higher stiffness values were observed in malignant FBLs for all 2D-SWE parameters than in benign ones (p < 0.001). 2D-SWE cutoff values were 82.6 kPa, 66.0 kPa and 53.6 kPa, respectively, for Emax, Emean, Emin and 330.8% for Eratio. The 2D-SWE parameter showing the best diagnostic accuracy was Emax (85.44%). Considering US BI-RADS 3 (n = 60) and 4a (n = 32) FBLs, Emax and Emean showed the best diagnostic accuracy (85.87% for both), without a statistically significant decrease in sensitivity (p = 0.7003 and p = 1, respectively). CONCLUSION: Our study provides new vendor-specific cutoff values for 2D-SWE, suggesting its possible clinical use in the adjunctive assessment of category US-BI-RADS 3 and 4a breast masses.
Authors: T V Bartolotta; R Ienzi; A Cirino; C Genova; F Ienzi; D Pitarresi; E Safina; M Midiri Journal: Radiol Med Date: 2011-03-07 Impact factor: 3.469
Authors: Christoph F Dietrich; Jeffrey Bamber; Annalisa Berzigotti; Simona Bota; Vito Cantisani; Laurent Castera; David Cosgrove; Giovanna Ferraioli; Mireen Friedrich-Rust; Odd Helge Gilja; Ruediger Stephan Goertz; Thomas Karlas; Robert de Knegt; Victor de Ledinghen; Fabio Piscaglia; Bogdan Procopet; Adrian Saftoiu; Paul S Sidhu; Ioan Sporea; Maja Thiele Journal: Ultraschall Med Date: 2017-04-13 Impact factor: 6.548
Authors: C Balleyguier; S Canale; W Ben Hassen; P Vielh; E H Bayou; M C Mathieu; C Uzan; C Bourgier; C Dromain Journal: Eur J Radiol Date: 2012-03-24 Impact factor: 3.528
Authors: J Bamber; D Cosgrove; C F Dietrich; J Fromageau; J Bojunga; F Calliada; V Cantisani; J-M Correas; M D'Onofrio; E E Drakonaki; M Fink; M Friedrich-Rust; O H Gilja; R F Havre; C Jenssen; A S Klauser; R Ohlinger; A Saftoiu; F Schaefer; I Sporea; F Piscaglia Journal: Ultraschall Med Date: 2013-04-04 Impact factor: 6.548